BBIO vs. BPMC, RETA, TPTX, PRGO, BHVN, ALNY, TEVA, GMAB, RPRX, and BGNE
Should you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Blueprint Medicines (BPMC), Reata Pharmaceuticals (RETA), Turning Point Therapeutics (TPTX), Perrigo (PRGO), Biohaven (BHVN), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BeiGene (BGNE).
Blueprint Medicines (NASDAQ:BPMC) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, community ranking, earnings, media sentiment and risk.
Blueprint Medicines has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.
Blueprint Medicines has higher revenue and earnings than BridgeBio Pharma. Blueprint Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.
Blueprint Medicines has a net margin of -102.15% compared to Blueprint Medicines' net margin of -246.24%. Blueprint Medicines' return on equity of 0.00% beat BridgeBio Pharma's return on equity.
Blueprint Medicines presently has a consensus target price of $103.94, indicating a potential downside of 1.54%. BridgeBio Pharma has a consensus target price of $47.62, indicating a potential upside of 69.99%. Given Blueprint Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Blueprint Medicines.
Blueprint Medicines received 375 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 68.25% of users gave BridgeBio Pharma an outperform vote while only 67.84% of users gave Blueprint Medicines an outperform vote.
In the previous week, BridgeBio Pharma had 10 more articles in the media than Blueprint Medicines. MarketBeat recorded 15 mentions for BridgeBio Pharma and 5 mentions for Blueprint Medicines. BridgeBio Pharma's average media sentiment score of 0.62 beat Blueprint Medicines' score of 0.47 indicating that Blueprint Medicines is being referred to more favorably in the media.
99.9% of BridgeBio Pharma shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by company insiders. Comparatively, 24.7% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
BridgeBio Pharma beats Blueprint Medicines on 11 of the 17 factors compared between the two stocks.
Get BridgeBio Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
BridgeBio Pharma Competitors List
Related Companies and Tools